Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer.
Erin
E
Bertino
Miguel A
MA
Villalona-Calero
Patrick
P
Ross
Michael
M
Grever
Gregory A
GA
Otterson
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D011292:Premedication
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
N Engl J Med. 1994 Jan 20;330(3):153-8
8043059
J Clin Oncol. 2010 Apr 10;28(11):1843-9
20231678
J Clin Oncol. 2004 Jun 1;22(11):2184-91
15169807
J Natl Cancer Inst. 1994 May 4;86(9):673-80
8158698